Products

Signal Tracker Data Platform Data Enrichment API Intelligence desk

Solutions

Deal Origination Executive Search For Sales Teams Corporate Development For Founders For Agencies For Investors Signal-Based Outbound Competitive Intelligence Funding Signals Competitor Monitoring

Explore

Companies Live Signals Markets Trends

Resources

Signal Checker Blog Integrations FAQ Contact Pricing
Login Start Free
Geneoscopy logo — Cancer Prevention | Diagnostics | Precision Medicine

Geneoscopy

Cancer Prevention | Diagnostics | Precision Medicine

Founded 2015 United States St. Louis, United States 60 employees Series B Total: $112.90M Biotechnology, Health Care

General Information

Company Name Geneoscopy
Founded Year 2015
Location United States St. Louis, United States +1
Employees 60
Industries Biotechnology, Health Care
Funding Stage Series B
Social

Get notified when Geneoscopy moves

Funding, new markets, leadership changes, hiring surges — one e-mail, only when something happens.

Free · no account needed

About Geneoscopy

Geneoscopy is a biotechnology startup founded in 2015 and headquartered in the United States. The company's mission is to empower patients and providers to transform gastrointestinal health through innovative diagnostics. Its lead diagnostic uses stool-derived eukaryotic RNA (seRNA) to detect colorectal cancer and precancerous adenomas. Notably, this device received a Breakthrough Device Designation from the FDA for its potential to reduce morbidity associated with colorectal cancer through advanced adenoma detection. This innovative approach has gained significant attention, resulting in a $105.00M Series B investment from a consortium of investors, including Cultivation Capital, BioGenerator, Innovatus Capital Partners, LabCorp, Lightchain, NT Investments, Morningside Venture Investments as of 16 November 2021. The company's strong focus on cancer prevention, diagnostics, and precision medicine positions it as a potential game-changer in the field. Moreover, Geneoscopy is not solely focused on colorectal cancer diagnostics. The company is also developing diagnostics for the diagnosis and management of inflammatory bowel disease in collaboration with biopharmaceutical companies and leading academic research institutions. Overall, Geneoscopy's innovative diagnostic technologies, strong investor backing, and commitment to advancing gastrointestinal health make it a promising player in the biotechnology and healthcare industries.

Taxonomy: Life Sciences, Noninvasive Diagnostic Screening, Colorectal Cancer Screening, GI Health, Precision Medicine, Companion Diagnostics, RNA Biomarkers, Inflammatory Bowel Disease (IBD)

Funding Rounds & Investors (4)

View All
Funding Stage Amount Investors Lead Investors Date
Series B •••••• 7
Investor Investor Investor Investor Investor Investor
•••• •••• 		16 Nov 2021
Series A •••••• 3
Investor Investor
•••• •••• 		02 Oct 2019
Seed Round •••••• - 13 Apr 2018
Seed Round •••••• - 01 Oct 2016

Geneoscopy Alternatives & Competitors

Geneoscopy vs
Myriad Genetics
Myriad Genetics United States

Leading molecular diagnostic testing & precision medicine company dedicated to advancing health and...

IPO
2902 employees
Biotechnology
Compare Geneoscopy vs Myriad Genetics
Geneoscopy vs
Advanced Cell Diagnostics (ACD)
Advanced Cell Diagnostics (ACD) United States

RNA expression like you've never seen before

Series C
143 employees
Biotechnology, Health Care
Compare Geneoscopy vs Advanced Cell Diagnostics (ACD)
Geneoscopy vs
Wayfinder Biosciences
Wayfinder Biosciences United States

RNA technologies for biomanufacturing and smart therapeutics.

Seed
13 employees
Biotechnology
Compare Geneoscopy vs Wayfinder Biosciences
Also compare with: Geneoscopy vs Digene Corporation Digene Corporation

FAQ About Geneoscopy

Cancer Prevention | Diagnostics | Precision Medicine
Geneoscopy was founded in 2015.
Geneoscopy is headquartered in St. Louis, United States.
Geneoscopy operates in the following industries: Biotechnology, Health Care.
Geneoscopy has approximately 60 employees.
Geneoscopy has completed 4 funding rounds, raising a total of $112.90M. The latest funding stage is Series B.
Top alternatives and competitors to Geneoscopy include Myriad Genetics, Advanced Cell Diagnostics (ACD), Wayfinder Biosciences, Digene Corporation, Flomics. These companies operate in related industries and serve comparable markets. You can compare them side by side on Bounce Watch.
Geneoscopy and Myriad Genetics are both companies in similar industries. Compare their funding, team size, growth signals, and market position on Bounce Watch to see which one fits your needs.

Don't just browse. Track.

Signal Tracker monitors Geneoscopy and millions of companies for funding rounds, hiring surges, product changes, and 40+ signal types — so you never miss an opportunity.

Start Tracking — Free

One analytics cookie (Google Analytics). Cookie Policy